EcoR1 Capital ARTV Position
Exited3-Fund ConvergenceEcoR1 Capital exited their position in Artiva Biotherapeutics, Inc. (ARTV) in Q1 2025, after holding the stock for 3 quarters.
The position was first reported in Q3 2024 and has been tracked across 3 quarterly 13F filings.
ARTV is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Allogeneic NK Cells in 655 days (Jan 31, 2028), making the timing of EcoR1's position particularly relevant.
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Full company profile →Short Interest
1.5%
0.8 days to cover
EcoR1 Capital ARTV Position History
Frequently Asked Questions
Does EcoR1 Capital own ARTV?
No. EcoR1 Capital exited their position in Artiva Biotherapeutics, Inc. (ARTV) in Q1 2025. They previously held the stock for 3 quarters.
How many hedge funds own ARTV?
3 specialist biotech hedge funds currently hold ARTV, including RA Capital Management, RTW Investments, Cormorant Asset Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did EcoR1 Capital first buy ARTV?
EcoR1 Capital's position in ARTV was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is EcoR1 Capital's ARTV position increasing or decreasing?
EcoR1 Capital completely exited their ARTV position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ARTVCompany Page →
All fund holders, insider trades, catalysts, and cash runway
EcoR1 CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →